Retina/Vitreous News

WAILEA, Hawaii — Gene therapy is a rapidly advancing innovation in the world of retinal diseases, according to a speaker at Retina 2024.

Aviceda Therapeutics announced positive safety and efficacy outcomes from part 1 of its phase 2/3 SIGLEC trial for AVD-104, which is being evaluated in patients with geographic atrophy secondary to age-related macular degeneration.

WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Danny A. Mammo, MD, presents data investigating the 0.18 mg fluocinolone acetonide implant for the treatment of noninfectious uveitis in the posterior segment.

WAILEA, Hawaii —NT-501, an encapsulated cell therapy for the treatment of macular telangiectasia type 2, met its primary endpoints across two phase 3 trials, according to a speaker at Retina 2024.

LumiThera announced the EUROLIGHT registry study will evaluate the safety, efficacy and biomarkers of photobiomodulation treatment for dry age-related macular degeneration.

WAILEA, Hawaii — Novel drug delivery methods could provide longer durability for posterior segment therapies, according to a speaker at Retina 2024.

Aviceda Therapeutics has enrolled the first patient in its GLYCO phase 2 clinical trial studying AVD-104, an engineered glycan nanoparticle developed to treat diabetic macular edema.

WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Ferhina S. Ali, MD, MPH, presents real-world data from the FARETINA-AMD study investigating faricimab for the treatment of neovascular age-related macular degeneration.

WAILEA, Hawaii — Clinicians need to balance the efficacy of geographic atrophy medications with the risks, according to a speaker at Retina 2024.

WAILEA, Hawaii — Artificial intelligence for diabetic retinopathy screening can be a valuable tool, but regulatory issues still need to be addressed, according to a speaker here.